Almost every family navigating liver transplant in India eventually hears the same three letters: MELD. It appears on lab reports, comes up in every consultation, and often becomes the number a family fixates on above all else. Yet very few patients are given a clear explanation of what the MELD score actually measures, how it is calculated, why the MELD score evolved to MELD-Na with the addition of serum sodium , or why two patients with the identical score can be in genuinely different clinical situations.

This guide goes beyond the basic explanation available in Liver Transplant in Chennai: The Complete Patient Guide. It covers exactly how the MELD score is calculated and why those specific lab values were chosen, what MELD-Na adds and why it matters, how exception points work for conditions the score alone does not capture, how the score is used in practice by transplant programmes in Tamil Nadu through TRANSTAN, and, most importantly, what the score does not measure, since this last point is often the difference between a good transplant outcome and a missed opportunity.

One of the commonest misunderstandings Dr. Manikandan Kathirvel encounters is families treating the MELD score as though it were a countdown clock or comparing one patient’s score directly with another’s. In reality, a MELD score is a statistical estimate of short-term mortality risk, not a measure of how unwell a patient appears or how long they have left. Two patients with exactly the same MELD score can have very different clinical situations depending on factors such as frailty, infections, liver cancer, nutritional status, and the overall trajectory of their disease. The number is important, but it should never be interpreted in isolation. 

Key Takeaways

• The original MELD score is calculated from bilirubin, creatinine, and INR. Most transplant programmes now use MELD-Na, which also incorporates serum sodium. and produces a number from 6 to 40 that estimates a patient’s risk of dying within three months without a transplant.
• Since 2016, most transplant programmes internationally use MELD-Na, which adds serum sodium to the original formula because low sodium independently predicts mortality in cirrhosis, even when the original three values look stable.
• Certain conditions, most notably liver cancer confined to the liver, are not accurately captured by the lab-based MELD score, which is why exception point systems exist internationally to reflect the real urgency of these cases.
• A MELD score is only one part of the clinical picture. Functional status, frailty, muscle wasting, infection burden, and quality of life all influence timing decisions in ways the number alone cannot capture.
• In Tamil Nadu, TRANSTAN uses MELD as the primary basis for deceased donor liver allocation, but registration timing, blood group compatibility, and clinical judgement all factor into how the score translates into an actual transplant.

What the MELD Score Actually Measures

The Model for End-Stage Liver Disease score, universally known by its acronym MELD, was originally developed in the early 2000s not for transplant allocation at all, but to predict survival in patients undergoing a procedure called a transjugular intrahepatic portosystemic shunt (TIPS), used to relieve complications of portal hypertension. As the American Association for the Study of Liver Diseases explains, the original 2000 study found MELD predicted survival in these patients more accurately than the older Child-Pugh classification, and the formula predicted mortality in liver disease so reliably that it was subsequently adapted for a much larger purpose: deciding who receives a deceased donor liver first.

At its core, MELD answers one specific question: what is this patient’s estimated risk of dying within the next three months if they do not receive a transplant? It does not measure quality of life, does not measure symptoms directly, and does not measure how a patient looks or feels on a given day. It measures the internal chemistry of liver failure using three blood tests, and converts that into a single number between 6 and 40.

This narrow, specific design is both the score’s greatest strength and its most important limitation. It is a strength because laboratory values are objective, reproducible, and cannot be influenced by how convincingly a patient describes their symptoms, which makes the allocation system fair and resistant to manipulation. It is a limitation because, as covered later in this guide, some of the sickest patients in genuine need of urgent transplant do not have laboratory values that reflect that urgency.

Why These Three Specific Lab Values

The original MELD score is calculated using bilirubin, creatinine, and INR, combined in a logarithmic formula. Each of these was chosen because it reflects a genuinely distinct aspect of liver failure, not because they were simply convenient to measure.

Bilirubin reflects the liver’s ability to process and excrete waste products from the breakdown of red blood cells. As liver function declines, bilirubin accumulates in the blood, causing the yellowing of skin and eyes known as jaundice. A rising bilirubin is one of the most direct chemical signals of worsening liver function.

INR (International Normalised Ratio) measures how long blood takes to clot. The liver produces the majority of the proteins responsible for clotting, so as liver function deteriorates, clotting becomes progressively impaired. A prolonged INR reflects this loss of synthetic liver function; it is not simply a measure of bleeding risk, but a proxy for how much of the liver’s manufacturing capacity remains intact.

Creatinine measures kidney function. This inclusion often surprises patients, since MELD is a liver disease score. The reason creatinine is included is that advanced liver disease frequently causes secondary kidney impairment, a relationship so well established in hepatology that it has its own name: hepatorenal syndrome. Deteriorating kidney function in a patient with liver disease is one of the strongest independent predictors of short-term mortality, which is why it was built directly into the formula rather than treated as a separate consideration.

The three values are combined using a specific logarithmic formula, not a simple average, because the relationship between rising values and mortality risk is not linear. Small changes in these values at the higher end of the range translate into much larger changes in actual mortality risk than the same numerical change would at the lower end.

MELD-Na: Why Sodium Was Added in 2016

For roughly the first fourteen years of MELD-based allocation, the score used only bilirubin, creatinine, and INR. In January 2016, transplant allocation systems in the United States, and subsequently many programmes internationally, adopted a revised version called MELD-Na, which incorporates serum sodium into the calculation.

The reason for this change was data, not theory. Research published in Gastroenterology (Kim et al., 2008) found that a one-unit decrease in serum sodium between 135 and 120 mEq/L corresponds to an increase in mortality risk equivalent to roughly a 1.6-point rise in MELD score, demonstrating that patients with low serum sodium had significantly higher mortality than their bilirubin, creatinine, and INR values alone would predict. Hyponatremia in cirrhosis is not a random laboratory abnormality. It develops as a direct consequence of advanced portal hypertension and the body’s compensatory hormonal response to it, meaning low sodium is itself a marker of how advanced the underlying liver disease has become, independent of what the original three values show.

The MELD-Na formula adjusts the original MELD score upward for patients with sodium below the normal range, with the adjustment becoming more significant as sodium drops further. A patient with a MELD score of 15 and normal sodium will have a MELD-Na close to 15. The same patient with a MELD score of 15 but a sodium of 125 will have a meaningfully higher MELD-Na, reflecting the additional mortality risk that low sodium independently carries.

This matters practically for one reason above all others: it means two patients can have the same original three-value MELD score and genuinely different levels of urgency. A patient with stable sodium and one with significant hyponatremia are not equivalent, even if their bilirubin, creatinine, and INR are identical, which is precisely why sodium was added rather than left out.

What a MELD Score Number Actually Means for a Patient

The MELD score ranges from 6 to 40. The table below sets out the general severity bands used across most transplant programmes, including in India:

MELD Score	General Meaning
6–14	Compensated or relatively stable liver disease in many patients
15–24	Advanced liver disease; transplant assessment is usually appropriate
25–34	High short-term mortality risk; transplant becomes increasingly urgent
35–40	Very high short-term mortality risk requiring urgent management

These bands are a useful general guide, but they should not be read as fixed thresholds that apply identically to every patient. The sections below explain why.

A common misunderstanding is treating MELD as a linear countdown, as though a score of 20 means twice the urgency of a score of 10, or that a specific score guarantees a specific timeline to transplant. Neither is accurate.

The relationship between MELD score and three-month mortality risk is exponential, not linear. The difference in risk between a MELD of 10 and a MELD of 15 is meaningfully smaller than the difference in risk between a MELD of 30 and a MELD of 35, even though both represent a five-point increase. This is precisely why the formula uses logarithms rather than simple addition: it is designed to reflect how liver failure actually behaves biologically, where risk accelerates disproportionately as the disease advances.

A second common misunderstanding is assuming the score is fixed. MELD is not a diagnosis assigned once. It is recalculated at intervals, sometimes every few days for hospitalised patients, sometimes every few months for stable outpatients on a waiting list, because the underlying blood values genuinely change over time. A patient’s score can rise during an infection or acute decompensation and fall again once that episode is treated. This is one of the reasons transplant programmes require regular blood testing even after a patient has been listed.

A third point, often the hardest for families to accept, is that a moderate or even low MELD score does not mean a patient is safe from serious risk. As covered in the next section, and as many transplant surgeons emphasise in practice, some of the most clinically concerning patients have scores that understate their actual danger.

MELD Exception Points: When the Score Underestimates Urgency

The clearest case where MELD underestimates urgency is hepatocellular carcinoma (HCC), liver cancer arising in a cirrhotic liver. A patient with a small, early-stage tumour can have entirely normal bilirubin, creatinine, and INR, producing a MELD score in the low teens despite facing real risk of the cancer progressing beyond the point where transplant remains curative.

Internationally, transplant allocation systems address this through exception point policies — assigning patients with HCC an adjusted score that reflects their tumour progression risk rather than their lab values alone.Although policies differ between allocation systems, transplant programmes recognise that certain conditions cannot be adequately prioritised by laboratory MELD score alone the calculated MELD is the starting point, not the sole determinant, for patients whose lab values don’t reflect their true clinical urgency.

HCC is the most common example, but it is not the only one. Severe symptoms from conditions like refractory encephalopathy or cholestatic disease can also justify earlier evaluation independent of what the MELD number shows.

Some of the patients who concern Dr. Manikandan Kathirvel the most are not necessarily those with the highest MELD scores. A patient with an early liver cancer may have excellent laboratory values and therefore a relatively low MELD score, yet delaying transplantation could allow the tumour to progress beyond transplant criteria. Equally, another patient with recurrent infections, severe frailty, or repeated episodes of encephalopathy may be significantly sicker than their laboratory score suggests. This is why transplant decisions are never based on the MELD score alone. 

What MELD Does Not Measure

Understanding what the MELD score leaves out is arguably as important as understanding what it includes, because these gaps directly affect how transplant timing decisions are actually made in clinical practice.

Frailty and functional status. Two patients with an identical MELD score can have very different physical reserves. One may still be walking, eating adequately, and managing daily activities. The other may be bedbound, unable to maintain nutrition, and losing muscle mass rapidly. The second patient is at meaningfully higher risk of a poor outcome, both while waiting and after surgery, despite an identical laboratory score.

Sarcopenia (muscle wasting). Progressive loss of muscle mass is extremely common in advanced liver disease and is not reflected anywhere in the MELD calculation. Sarcopenia is independently associated with worse waitlist mortality and worse post-transplant recovery. This is one of the reasons nutritional and physical assessment forms a standard part of every transplant evaluation, regardless of MELD score.

Recurrent infections. Patients with cirrhosis who experience repeated infections, particularly spontaneous bacterial peritonitis, face elevated mortality risk that is not fully captured by a single MELD calculation, since infection episodes may resolve before the next scheduled blood test, temporarily normalising the values a score is calculated from.

Quality of life and symptom burden. Severe, difficult-to-control itching from cholestatic liver disease, refractory encephalopathy affecting a patient’s ability to function safely at home, or the practical burden of repeated large-volume paracentesis for ascites can represent genuine indications for earlier transplant consideration, independent of what the MELD score shows.

Disease trajectory. A patient whose MELD score has climbed steadily over several months is in a different clinical situation than a patient with the same current score whose values have been stable for a year. The trend matters, not only the snapshot.

This is why transplant surgeons do not, and should not, make decisions from a MELD number in isolation. The score is a critical, objective starting point for prioritisation, particularly for deceased donor allocation, where a fair and consistent system is essential. But the actual decision about whether and when an individual patient needs transplant evaluation and listing depends on the complete clinical picture.

How TRANSTAN Uses MELD in Tamil Nadu

For a complete explanation of how the deceased donor allocation process works from registration through to notification, see The TRANSTAN Process: How Deceased Donor Liver Transplants Work in Tamil Nadu.

TRANSTAN, the Transplant Authority of Tamil Nadu, defines MELD in the same terms used internationally: a scale from 6 (least ill) to 40 (gravely ill), where patients with higher scores are given priority for deceased donor allocation because they carry the greater estimated risk within the next three months. This is stated directly in TRANSTAN’s own public guidance, and it forms the clinical backbone of how the waiting list is ordered.

But the mechanics of how that plays out in practice involve more than a single number on a list, and understanding these mechanics matters for any family navigating the system.

Registration is hospital-specific, but portable. A patient registers for the deceased donor waiting list through one participating hospital at a time, and that hospital maintains the patient’s position. If a family later transfers a patient’s registration to a different hospital, for whatever reason, TRANSTAN has policies governing transfer of registration between participating hospitals. Patients considering transfer should discuss the implications with their transplant team

Not every patient is prioritised by MELD score alone. TRANSTAN’s allocation framework distinguishes between a standard list, where relative position depends primarily on MELD score and time registered, and an urgent category reserved for a small number of specific, acute clinical situations, such as fulminant hepatic failure, hepatic artery thrombosis following a prior transplant, or primary non-function of a newly transplanted graft. Patients in these urgent categories do not need to accumulate waiting time on the list in the way standard patients do, because their situation is, by definition, immediately life-threatening regardless of what a calculated MELD score would otherwise suggest. This is a direct, practical illustration of the broader point made earlier in this guide: MELD is the primary tool, but the allocation system still has mechanisms to recognise urgency that the number alone would not capture quickly enough.

For families on the TRANSTAN deceased donor waiting list, a few practical points follow from how the system works.

Registering with TRANSTAN as early as a transplant centre judges appropriate is generally advisable, since registration itself does not commit a family to proceeding immediately, and it allows the MELD-based priority system to work in the patient’s favour as their score evolves over time.

Because MELD scores are reassessed periodically rather than fixed at registration, patients remain responsible for regular follow-up blood testing to ensure their position in the system accurately reflects their current clinical status.

Because deceased donor availability depends on organ donation rates and blood group distribution as well as MELD score, two patients with identical scores may experience different waiting times depending on their blood group and how many compatible organs become available during their waiting period.

Families should also understand that a sudden, severe deterioration, of the kind that would qualify for the urgent category, changes a patient’s position in the system immediately rather than waiting for the next scheduled MELD recalculation, which is one more reason close communication with the transplant team matters throughout the waiting period.

If Your Family Has Been Given a MELD Score and Has Questions

A MELD score on a lab report tells one part of the story. Frailty, functional status, infection history, and disease trajectory tell the rest. Dr. Manikandan Kathirvel sees patients for liver transplant evaluation at Gleneagles Hospital, Chennai, to assess the full clinical picture, not just the number. No prior referral is required. Request an Evaluation →